Eli Lilly, Incyte: Baricitinib Improves Hair Regrowth in Alopecia Areata
April 20 2021 - 7:47AM
Dow Jones News
By Colin Kellaher
Eli Lilly & Co. and Incyte Corp. on Tuesday said a second
Phase 3 study of baricitinib showed improved hair regrowth in
patients with the autoimmune disorder alopecia areata.
The companies said data from the study are consistent with
findings from the first Phase 3 trial, with a statistically
significant proportion of patients treated with baricitinib
achieving the primary endpoint of hair regrowth across the two
dosing regimens at 36 weeks compared with those treated with
placebo.
There are currently no FDA-approved treatments for alopecia
areata, which can cause unpredictable hair loss on the scalp, face
and other areas of the body. Eli Lilly and Incyte said data from
the two studies will support a regulatory submission to achieve a
potential first-in-disease approval.
Indianapolis-based Eli Lilly signed an exclusive worldwide
license and collaboration agreement with Incyte, a Wilmington,
Del., biopharmaceutical company, in late 2009 to develop and
commercialize baricitinib and other compounds for inflammatory and
autoimmune diseases.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
April 20, 2021 07:32 ET (11:32 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Incyte (NASDAQ:INCY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Incyte (NASDAQ:INCY)
Historical Stock Chart
From Apr 2023 to Apr 2024